Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival-Reference-Cited by-同舟云学术

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Published:2018-05-13 Issue:9 Volume:97 Page:1671-1682
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Katodritou Eirini,Kyrtsonis Marie-Christine,Delimpasi Sosana,Kyriakou Despoina,Symeonidis Argiris,Spanoudakis Emmanouil,Vasilopoulos Georgios,Anagnostopoulos Achilles,Kioumi Anna,Zikos Panagiotis,Aktypi Anthi,Briasoulis Evangelos,Megalakaki Aikaterini,Repousis Panayiotis,Adamopoulos Ioannis,Gogos Dimitrios,Kotsopoulou Maria,Pappa Vassiliki,Papadaki Eleni,Fotiou Despoina,Nikolaou Eftychia,Giannopoulou Evlambia,Hatzimichael Eleftheria,Giannakoulas Nikolaos,Douka Vassiliki,Kokoviadou Kyriaki,Timotheatou Despoina,Terpos Evangelos

Funder

Genesis Pharma

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3361-2/fulltext.html

Reference32 articles.

1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060. https://doi.org/10.1056/NEJMra1011442

2. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5

3. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S (2015) Treatment options for relapsed and refractory multiple myeloma. Blood 125(20):3085–3099. https://doi.org/10.1182/blood-2014-11-568923